Emerging Drug Developer: Gemin X Pharmaceuticals

Gemin X Pharmaceuticals

Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. There were stints at AstraZeneca and Merck capped by a role as global head of clinical development and medical affairs for Novartis. 

Now, though, he's made the leap from top executive at big pharma to biotech entrepreneur, taking the top job at Gemin X Pharmaceuticals just weeks before a third venture round reaped $38 million, bringing the company to more than $90 million in total money raised as it heads through the mid-stage point on its lead therapy. Article

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.